Insilico Medicine (HKG:3696) said it entered into a strategic alliance with Bora Pharmaceuticals (TPE:6472) to collaborate on AI-driven drug discovery and development under a framework that could be valued at over $2.5 billion if fully implemented.
The proposed collaboration, subject to the execution of definitive agreements, will combine Insilico's Pharma.AI platform for target discovery, generative chemistry and molecule optimization with Bora's drug development, manufacturing, quality and commercialization capabilities.
The alliance aims to integrate AI-enabled drug discovery with development and manufacturing to accelerate the delivery of medicines for patients with unmet medical needs, according to a Wednesday news release.